Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer

AMPLIFY-7P did not meet the pre-specified primary endpoint of disease-free survival (“DFS”) in the intent-to-treat population.Randomization ...
MSN on MSN

Enliven Therapeutics reports positive phase 1 CML data and FDA alignment for phase 3 trial (ELVN)

Updated ELVN-001 results showed strong molecular response rates in previously treated CML patients, while the FDA aligned ...

Cynata clears key European regulatory step toward future Phase 3 in acute graft versus host disease

Cynata Therapeutics has received a Positive Opinion from the European Medicines Agency’s Paediatric Committee (PDCO) on its ...

Apogee Therapeutics Maps Phase 3 Push for Zumilokibart, Backed by Blackstone Funding

Apogee Therapeutics (NASDAQ:APGE) executives outlined plans to advance zumilokibart, the company’s IL-13-targeting antibody, ...